Circulation, Vol 79, 8-15, Copyright © 1989 by American Heart Association
DJ Gordon, JL Probstfield, RJ Garrison, JD Neaton, WP Castelli, JD Knoke, DR Jacobs Jr, S Bangdiwala and HA Tyroler
The British Regional Heart Study (BRHS) reported in 1986 that much of the
inverse relation of high-density lipoprotein cholesterol (HDLC) and
incidence of coronary heart disease was eliminated by covariance
adjustment. Using the proportional hazards model and adjusting for age,
blood pressure, smoking, body mass index, and low-density lipoprotein
cholesterol, we analyzed this relation separately in the Framingham Heart
Study (FHS), Lipid Research Clinics Prevalence Mortality Follow- up Study
(LRCF) and Coronary Primary Prevention Trial (CPPT), and Multiple Risk
Factor Intervention Trial (MRFIT). In CPPT and MRFIT (both randomized
trials in middle-age high-risk men), only the control groups were analyzed.
A 1-mg/dl (0.026 mM) increment in HDLC was associated with a significant
coronary heart disease risk decrement of 2% in men (FHS, CPPT, and MRFIT)
and 3% in women (FHS). In LRCF, where only fatal outcomes were documented,
a 1-mg/dl increment in HDLC was associated with significant 3.7% (men) and
4.7% (women) decrements in cardiovascular disease mortality rates. The 95%
confidence intervals for these decrements in coronary heart and
cardiovascular disease risk in the four studies overlapped considerably,
and all contained the range 1.9-2.9%. HDLC levels were essentially
unrelated to non- cardiovascular disease mortality. When differences in
analytic methodology were eliminated, a consistent inverse relation of HDLC
levels and coronary heart disease event rates was apparent in BRHS as well
as in the four American studies.
ARTICLES
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
Lipid Metabolism-Atherogenesis Branch, National Institutes of Health, Bethesda, Maryland, MD 20892.
This article has been cited by other articles:
 |
|
 |
|
  The Emerging Risk Factors Collaboration Major Lipids, Apolipoproteins, and Risk of Vascular Disease JAMA, November 11, 2009; 302(18): 1993 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M.S. Lee, M. D. Robson, L.-M. Yu, C. C. Shirodaria, C. Cunnington, I. Kylintireas, J. E. Digby, T. Bannister, A. Handa, F. Wiesmann, et al. Effects of high-dose modified-release nicotinic Acid on atherosclerosis and vascular function a randomized, placebo-controlled, magnetic resonance imaging study. J. Am. Coll. Cardiol., November 3, 2009; 54(19): 1787 - 1794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Z. Willey, Q. Xu, B. Boden-Albala, M. C. Paik, Y. P. Moon, R. L. Sacco, and M. S. V. Elkind Lipid Profile Components and Risk of Ischemic Stroke: The Northern Manhattan Study (NOMAS) Arch Neurol, November 1, 2009; 66(11): 1400 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Grover, M. Kaouache, L. Joseph, P. Barter, and J. Davignon Evaluating the Incremental Benefits of Raising High-Density Lipoprotein Cholesterol Levels During Lipid Therapy After Adjustment for the Reductions in Other Blood Lipid Levels Arch Intern Med, October 26, 2009; 169(19): 1775 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur. Heart J., October 12, 2009; (2009) ehp399v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Superko Cardiovascular event risk: high-density lipoprotein and paraoxonase. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1246 - 1248. [Full Text] [PDF]
|
|
|
|
|
|
S. Rashid, M. Marcil, I. Ruel, and J. Genest Identification of a novel human cellular HDL biosynthesis defect Eur. Heart J., September 2, 2009; 30(18): 2204 - 2212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Miller Dyslipidemia and cardiovascular risk: the importance of early prevention QJM, September 1, 2009; 102(9): 657 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Walter Interrelationships Among HDL Metabolism, Aging, and Atherosclerosis Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1244 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Monda, C. M. Ballantyne, and K. E. North Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study J. Lipid Res., August 1, 2009; 50(8): 1685 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Tavakol, F. G. Vincenti, H. Assadi, M. J. Frederick, S. J. Tomlanovich, J. P. Roberts, and A. M. Posselt Long-Term Renal Function and Cardiovascular Disease Risk in Obese Kidney Donors Clin. J. Am. Soc. Nephrol., July 1, 2009; 4(7): 1230 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kodama, K. Saito, S. Tanaka, M. Maki, Y. Yachi, M. Asumi, A. Sugawara, K. Totsuka, H. Shimano, Y. Ohashi, et al. Cardiorespiratory Fitness as a Quantitative Predictor of All-Cause Mortality and Cardiovascular Events in Healthy Men and Women: A Meta-analysis JAMA, May 20, 2009; 301(19): 2024 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Sacks, L. L. Rudel, A. Conner, H. Akeefe, G. Kostner, T. Baki, G. Rothblat, M. de la Llera-Moya, B. Asztalos, T. Perlman, et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo J. Lipid Res., May 1, 2009; 50(5): 894 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Goldberg, M. Temprosa, S. Haffner, T. J. Orchard, R. E. Ratner, S. E. Fowler, K. Mather, S. Marcovina, C. Saudek, M. J. Matulik, et al. Effect of Progression From Impaired Glucose Tolerance to Diabetes on Cardiovascular Risk Factors and Its Amelioration by Lifestyle and Metformin Intervention: The Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group Diabetes Care, April 1, 2009; 32(4): 726 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Karalis Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Mayo Clin. Proc., April 1, 2009; 84(4): 345 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-A. Rye, C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter The metabolism and anti-atherogenic properties of HDL J. Lipid Res., April 1, 2009; 50(Supplement): S195 - S200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Patel, B. G. Drew, S. Nakhla, S. J. Duffy, A. J. Murphy, P. J. Barter, K.-A. Rye, J. Chin-Dusting, A. Hoang, D. Sviridov, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol., March 17, 2009; 53(11): 962 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Harrison, D. J. O'Gorman, N. McCaffrey, M. T. Hamilton, T. W. Zderic, B. P. Carson, and N. M. Moyna Influence of acute exercise with and without carbohydrate replacement on postprandial lipid metabolism J Appl Physiol, March 1, 2009; 106(3): 943 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Oslakovic, M. J. Krisinger, A. Andersson, M. Jauhiainen, C. Ehnholm, and B. Dahlback Anionic Phospholipids Lose Their Procoagulant Properties When Incorporated into High Density Lipoproteins J. Biol. Chem., February 27, 2009; 284(9): 5896 - 5904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakanishi, R. Vikstedt, S. Soderlund, M. Lee-Rueckert, A. Hiukka, C. Ehnholm, M. Muilu, J. Metso, J. Naukkarinen, L. Palotie, et al. Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity J. Lipid Res., February 1, 2009; 50(2): 183 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mackness and M. Mackness High-density lipoprotein: why all the fuss? Ann Clin Biochem, January 1, 2009; 46(1): 5 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mukherjee, K. T. Locke, B. Miao, D. Meyers, H. Monshizadegan, R. Zhang, D. Search, D. Grimm, M. Flynn, K. M. O'Malley, et al. Novel Peroxisome Proliferator-Activated Receptor {alpha} Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 716 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tybjaerg-Hansen, B. G. Nordestgaard, and R. Frikke-Schmidt ABCA1 Gene Mutations, HDL Cholesterol Levels, and Risk of Ischemic Heart Disease--Reply JAMA, November 5, 2008; 300(17): 1998 - 1998. [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Koropatnick, J. Kimbell, R. Chen, J. S. Grove, T. A. Donlon, K. H. Masaki, B. L. Rodriguez, B. J. Willcox, K. Yano, and J. D. Curb A Prospective Study of High-Density Lipoprotein Cholesterol, Cholesteryl Ester Transfer Protein Gene Variants, and Healthy Aging in Very Old Japanese-American Men J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2008; 63(11): 1235 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Stylianou, S. R. Langley, K. Walsh, Y. Chen, C. Revenu, and B. Paigen Differences in DBA/1J and DBA/2J reveal lipid QTL genes J. Lipid Res., November 1, 2008; 49(11): 2402 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mulya, J.-Y. Lee, A. K. Gebre, E. Y. Boudyguina, S.-K. Chung, T. L. Smith, P. L. Colvin, X.-C. Jiang, and J. S. Parks Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL J. Lipid Res., November 1, 2008; 49(11): 2390 - 2401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mosca, H. Mochari, M. Liao, A. H. Christian, D. J. Edelman, B. Aggarwal, and M. C. Oz A Novel Family-Based Intervention Trial to Improve Heart Health: FIT Heart: Results of a Randomized Controlled Trial Circ Cardiovasc Qual Outcomes, November 1, 2008; 1(2): 98 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-Q. Peng, G. Brubaker, Z. Wu, L. Zheng, B. Willard, M. Kinter, S. L. Hazen, and J. D. Smith Apolipoprotein A-I Tryptophan Substitution Leads to Resistance to Myeloperoxidase-Mediated Loss of Function Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 2063 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Postgrad. Med. J., November 1, 2008; 84(997): 590 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Hime, A. S. Black, J. J. Bulgrien, and L. K. Curtiss Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP J. Lipid Res., October 1, 2008; 49(10): 2113 - 2123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Rosenzweig, E. Ferrannini, S. M. Grundy, S. M. Haffner, R. J. Heine, E. S. Horton, and R. Kawamori Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3671 - 3689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Frikke-Schmidt, B. G. Nordestgaard, M. C. A. Stene, A. A. Sethi, A. T. Remaley, P. Schnohr, P. Grande, and A. Tybjaerg-Hansen Association of Loss-of-Function Mutations in the ABCA1 Gene With High-Density Lipoprotein Cholesterol Levels and Risk of Ischemic Heart Disease JAMA, June 4, 2008; 299(21): 2524 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-H. Zhang, V. S. Kamanna, M. C. Zhang, and M. L. Kashyap Niacin inhibits surface expression of ATP synthase {beta} chain in HepG2 cells: implications for raising HDL J. Lipid Res., June 1, 2008; 49(6): 1195 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Wool, C. A. Reardon, and G. S. Getz Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties J. Lipid Res., June 1, 2008; 49(6): 1268 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wild and C. D Byrne Time to rethink high-density lipoprotein? Heart, June 1, 2008; 94(6): 692 - 694. [Full Text] [PDF]
|
|
|
|
|
|
D J Hausenloy and D M Yellon Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels Heart, June 1, 2008; 94(6): 706 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Grarup, C. H. Andreasen, M. K. Andersen, A. Albrechtsen, A. Sandbaek, T. Lauritzen, K. Borch-Johnsen, T. Jorgensen, O. Schmitz, T. Hansen, et al. The -250G>A Promoter Variant in Hepatic Lipase Associates with Elevated Fasting Serum High-Density Lipoprotein Cholesterol Modulated by Interaction with Physical Activity in a Study of 16,156 Danish Subjects J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2294 - 2299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Davidson, P. M. Meyer, S. Haffner, S. Feinstein, R. D'Agostino Sr, G. T. Kondos, A. Perez, Z. Chen, and T. Mazzone Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus Circulation, April 22, 2008; 117(16): 2123 - 2130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Griel, Y. Cao, D. D. Bagshaw, A. M. Cifelli, B. Holub, and P. M. Kris-Etherton A Macadamia Nut-Rich Diet Reduces Total and LDL-Cholesterol in Mildly Hypercholesterolemic Men and Women J. Nutr., April 1, 2008; 138(4): 761 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Anderson and A. B. Salgado Letter Regarding Article by Leeper et al, "Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival" Circulation, March 4, 2008; 117(9): e174 - e174. [Full Text] [PDF]
|
|
|
|
|
|
V. Stangl, V. Witzel, G. Baumann, and K. Stangl Current diagnostic concepts to detect coronary artery disease in women Eur. Heart J., March 2, 2008; 29(6): 707 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferns and V. Keti HDL-cholesterol modulation and its impact on the management of cardiovascular risk Ann Clin Biochem, March 1, 2008; 45(2): 122 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Catalano, E. Duchene, Z. Julia, W. Le Goff, E. Bruckert, M. J. Chapman, and M. Guerin Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects J. Lipid Res., March 1, 2008; 49(3): 635 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. van der Steeg, I. Holme, S. M. Boekholdt, M. L. Larsen, C. Lindahl, E. S.G. Stroes, M. J. Tikkanen, N. J. Wareham, O. Faergeman, A. G. Olsson, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 634 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. P. Berbee, S. P. Mooijaart, A. J. M. de Craen, L. M. Havekes, D. van Heemst, P. C. N. Rensen, and R. G. J. Westendorp Plasma Apolipoprotein CI Protects Against Mortality From Infection in Old Age J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2008; 63(2): 122 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.-P. Tang, L.-S. Wang, L. Yang, B. Zhou, H.-J. Gu, Q.-M. Sun, R.-H. Cong, H.-J. Zhu, and B. Wang Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population J. Lipid Res., February 1, 2008; 49(2): 369 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Feng, F. Jacobs, E. Van Craeyveld, C. Brunaud, J. Snoeys, M. Tjwa, S. Van Linthout, and B. De Geest Human ApoA-I Transfer Attenuates Transplant Arteriosclerosis via Enhanced Incorporation of Bone marrow-derived Endothelial Progenitor Cells Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 278 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Lavie and R. V. Milani Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 56 - 58. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sritara, P. Patoomanunt, M. Woodward, K. Narksawat, S. Tulyadachanon, W. Ratanachaiwong, C. Sritara, F. Barzi, S. Yamwong, and S. Tanomsup Associations Between Serum Lipids and Causes of Mortality in a Cohort of 3499 Urban Thais: The Electricity Generating Authority of Thailand (EGAT) Study Angiology, January 1, 2008; 58(6): 757 - 763. [Abstract] [PDF]
|
|
|
|
|
|
P. J. Barter and K.-A. Rye Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome? Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 39 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ruixing, F. Qiming, Y. Dezhai, L. Shuquan, L. Weixiong, P. Shangling, W. Hai, Y. Yongzhong, H. Feng, and Q. Shuming Comparison of demography, diet, lifestyle, and serum lipid levels between the Guangxi Bai Ku Yao and Han populations J. Lipid Res., December 1, 2007; 48(12): 2673 - 2681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barter, M. Caulfield, M. Eriksson, S. M. Grundy, J. J.P. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.-C. Tardif, D. D. Waters, et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events N. Engl. J. Med., November 22, 2007; 357(21): 2109 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Leonard, J. D. Joss, D. J. Mustacich, D. H. Blatt, Y. S. Lee, and M. G. Traber Effects of vitamin E on cholesterol levels of hypercholesterolemic patients receiving statins Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2257 - 2266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barter, A. M. Gotto, J. C. LaRosa, J. Maroni, M. Szarek, S. M. Grundy, J. J.P. Kastelein, V. Bittner, J.-C. Fruchart, and the Treating to New Targets Investigators HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events N. Engl. J. Med., September 27, 2007; 357(13): 1301 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P J Twomey and D R Pledger HDL-cholesterol and triglycerides: an overlooked issue? J. Clin. Pathol., September 1, 2007; 60(9): 1065 - 1066. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Mytton, A. Gray, M. Rayner, and H. Rutter Could targeted food taxes improve health? J Epidemiol Community Health, August 1, 2007; 61(8): 689 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women JAMA, July 18, 2007; 298(3): 299 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Morehouse, E. D. Sugarman, P.-A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits J. Lipid Res., June 1, 2007; 48(6): 1263 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baba, M. Natsume, A. Yasuda, Y. Nakamura, T. Tamura, N. Osakabe, M. Kanegae, and K. Kondo Plasma LDL and HDL Cholesterol and Oxidized LDL Concentrations Are Altered in Normo- and Hypercholesterolemic Humans after Intake of Different Levels of Cocoa Powder J. Nutr., June 1, 2007; 137(6): 1436 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M S Lee and R. P Choudhury Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets Heart, May 1, 2007; 93(5): 559 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.P. Kastelein, S. I. van Leuven, L. Burgess, G. W. Evans, J. A. Kuivenhoven, P. J. Barter, J. H. Revkin, D. E. Grobbee, W. A. Riley, C. L. Shear, et al. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia N. Engl. J. Med., April 19, 2007; 356(16): 1620 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Nissen, J.-C. Tardif, S. J. Nicholls, J. H. Revkin, C. L. Shear, W. T. Duggan, W. Ruzyllo, W. B. Bachinsky, G. P. Lasala, E. M. Tuzcu, et al. Effect of Torcetrapib on the Progression of Coronary Atherosclerosis N. Engl. J. Med., March 29, 2007; 356(13): 1304 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Grant and J. B. Meigs Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes: An unmet challenge for cardiovascular risk reduction Diabetes Care, March 1, 2007; 30(3): 479 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sanossian, J. L. Saver, M. Navab, and B. Ovbiagele High-Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment Stroke, March 1, 2007; 38(3): 1104 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Milani and C. J. Lavie Cholesteryl Ester Transfer Protein Inhibition: The Next Frontier in Combating Coronary Artery Disease? J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1791 - 1792. [Full Text] [PDF]
|
|
|
|
|
|
C. W. Joyce, E. M. Wagner, F. Basso, M. J. Amar, L. A. Freeman, R. D. Shamburek, C. L. Knapper, J. Syed, J. Wu, B. L. Vaisman, et al. ABCA1 Overexpression in the Liver of LDLr-KO Mice Leads to Accumulation of Pro-atherogenic Lipoproteins and Enhanced Atherosclerosis J. Biol. Chem., November 3, 2006; 281(44): 33053 - 33065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Kerwin, K. D. O'Brien, M. S. Ferguson, N. Polissar, T. S. Hatsukami, and C. Yuan Inflammation in Carotid Atherosclerotic Plaque: A Dynamic Contrast-enhanced MR Imaging Study Radiology, November 1, 2006; 241(2): 459 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Pedersen The gap between theory and practice: what do the trials tell us? Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F10 - F16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bruckert Epidemiology of low HDL-cholesterol: results of studies and surveys Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F17 - F22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Drexel Reducing risk by raising HDL-cholesterol: the evidence Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F23 - F29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Stylianou, S.-W. Tsaih, K. DiPetrillo, N. Ishimori, R. Li, B. Paigen, and G. Churchill Complex Genetic Architecture Revealed by Analysis of High-Density Lipoprotein Cholesterol in Chromosome Substitution Strains and F2 Crosses Genetics, October 1, 2006; 174(2): 999 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barter and K.-A. Rye The Argument Against the Appropriateness of Over-the-Counter Statins Circulation, September 19, 2006; 114(12): 1315 - 1320. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Steiner Implications of the global diabetes epidemic Diabetes and Vascular Disease Research, September 1, 2006; 3(1_suppl): S2 - S5. [Abstract] [PDF]
|
|
|
|
|
|
T. R Pedersen, G. Assmann, J.-P. Bassand, M J. Chapman, R. Erbel, and C. Sirtori Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment Diabetes and Vascular Disease Research, September 1, 2006; 3(2_suppl): S1 - S12. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Vogt, U. Kassner, U. Hostalek, and E. Steinhagen-Thiessen NAUTILUS (Safety and tolerability of Niaspan(R)): a subgroup analysis in patients with diabetes The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 127 - 133. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Barcelo, F. Barbe, M. de la Pena, M. Vila, G. Perez, J. Pierola, J. Duran, and A. G. N. Agusti Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur. Respir. J., April 1, 2006; 27(4): 756 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Tovar and D. B. Schering Management of Dyslipidemia in Special Populations Journal of Pharmacy Practice, April 1, 2006; 19(2): 63 - 78. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Ma, Y. Li, D. E. Chiriboga, B. C. Olendzki, J. R. Hebert, W. Li, K. Leung, A. R. Hafner, and I. S. Ockene Association between Carbohydrate Intake and Serum Lipids. J. Am. Coll. Nutr., April 1, 2006; 25(2): 155 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barter and K.-A. Rye Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism? Circulation, March 28, 2006; 113(12): 1553 - 1555. [Full Text] [PDF]
|
|
|
|
|
|
R. W. Clark, R. B. Ruggeri, D. Cunningham, and M. J. Bamberger Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action J. Lipid Res., March 1, 2006; 47(3): 537 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barter and J. J.P. Kastelein Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease J. Am. Coll. Cardiol., February 7, 2006; 47(3): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Arbones-Mainar, M. A. Navarro, S. Acin, M. A. Guzman, C. Arnal, J. C. Surra, R. Carnicer, H. M. Roche, and J. Osada Trans-10, cis-12- and cis-9, trans-11-Conjugated Linoleic Acid Isomers Selectively Modify HDL-Apolipoprotein Composition in Apolipoprotein E Knockout Mice J. Nutr., February 1, 2006; 136(2): 353 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kim and B. M Popkin Commentary: Understanding the epidemiology of overweight and obesity--a real global public health concern Int. J. Epidemiol., February 1, 2006; 35(1): 60 - 67. [Full Text] [PDF]
|
|
|
|
|
|
R. Ohashi, H. Mu, X. Wang, Q. Yao, and C. Chen Reverse cholesterol transport and cholesterol efflux in atherosclerosis QJM, December 1, 2005; 98(12): 845 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. de Vries, F. G. Perton, G. M. Dallinga-Thie, A. M. van Roon, B. H.R. Wolffenbuttel, A. van Tol, and R. P.F. Dullaart Plasma Cholesteryl Ester Transfer Is a Determinant of Intima-Media Thickness in Type 2 Diabetic and Nondiabetic Subjects: Role of CETP and Triglycerides Diabetes, December 1, 2005; 54(12): 3554 - 3559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pischon, C. J. Girman, F. M. Sacks, N. Rifai, M. J. Stampfer, and E. B. Rimm Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men Circulation, November 29, 2005; 112(22): 3375 - 3383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. F Van Gaal, F. Peiffer, and D. Ballaux Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 344 - 350. [Abstract] [PDF]
|
|
|
|
|
|
D.-Q. Peng, Z. Wu, G. Brubaker, L. Zheng, M. Settle, E. Gross, M. Kinter, S. L. Hazen, and J. D. Smith Tyrosine Modification Is Not Required for Myeloperoxidase-induced Loss of Apolipoprotein A-I Functional Activities J. Biol. Chem., October 7, 2005; 280(40): 33775 - 33784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Lee, J. M. Timmins, A. Mulya, T. L. Smith, Y. Zhu, E. M. Rubin, J. W. Chisholm, P. L. Colvin, and J. S. Parks HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidney J. Lipid Res., October 1, 2005; 46(10): 2233 - 2245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Asztalos, M. de la Llera-Moya, G. E. Dallal, K. V. Horvath, E. J. Schaefer, and G. H. Rothblat Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux J. Lipid Res., October 1, 2005; 46(10): 2246 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Nambi and C. M. Ballantyne Fat, Fit, and Leading the Charge: The Evolution of Measuring High-Density Lipoprotein Subpopulations Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2013 - 2015. [Full Text] [PDF]
|
|
|
|
|
|
F. Espinosa-Larranaga, M. Vejar-Jalaf, and R. Medina-Santillan The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor Diabetes and Vascular Disease Research, October 1, 2005; 2(1_suppl): S1 - S8. [Abstract] [PDF]
|
|
|
|
|
|
J. Mukuddem-Petersen, W. Oosthuizen, and J. C. Jerling A Systematic Review of the Effects of Nuts on Blood Lipid Profiles in Humans J. Nutr., September 1, 2005; 135(9): 2082 - 2089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Vaughan and J. F. Oram ABCG1 Redistributes Cell Cholesterol to Domains Removable by High Density Lipoprotein but Not by Lipid-depleted Apolipoproteins J. Biol. Chem., August 26, 2005; 280(34): 30150 - 30157. [Abstract] [Full Text] [PDF]
|
|